Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience

Stephen J. Lemon, Susan T. Tinley, Ramon M. Fusaro, Henry T. Lynch

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BACKGROUND. Hereditary cancer accounts for 5-10% of the estimated 1.38 million cancer cases in 1997 and requires an approach to cancer prevention that is distinct from its sporadic counterpart based on its differing natural history. The laboratory advances in the molecular biology of hereditary cancer have recently resulted in the development of specialized hereditary cancer clinics with both broad and syndrome specific hereditary cancer assessment capabilities. A key question is how well these clinics can accomplish this new mission. METHODS. A total of 58 people underwent hereditary cancer risk assessment in the Creighton University Hereditary Cancer Prevention Clinic from September of 1995 to September of 1996. Assessment included construction of a detailed pedigree and a cancer-directed medical history and physical examination. Cancer education, genetic counseling, the option of DNA testing when appropriate, and cancer prevention recommendations based on cancer risk were provided. RESULTS. The 58 patients were comprised of 51 females (88%) and 7 males (12%) predominantly from the Omaha, Nebraska geographic region. Forty patients (69%) were cancer unaffected whereas 18 (31%) were cancer affected; patient age ranged from 6 to 70 years with a mean age of 40 years. Thirty (52%) of the patient families were diagnosed with a hereditary cancer syndrome, 24 (41%) were diagnosed with familial cancer risk, and 4 (7%) were diagnosed with sporadic cancer risk. Of the 30 families with hereditary cancer syndromes, only 4 (13%) individuals have so far undergone DNA testing due to a variety of emotional, financial, insurance, and technical barriers. CONCLUSIONS. The authors have successfully implemented a clinically applicable hereditary cancer prevention program based on their expertise in hereditary cancer risk assessment that offers DNA testing through a commercial laboratory to patients diagnosed with hereditary cancer syndromes. However, a number of barriers to DNA evaluations exist that will require discussion among the medical, legislative, insurance, and lay communities in addition to further research in hereditary cancer risk assessment, genetic counseling, and cancer prevention strategies.

Original languageEnglish
Pages (from-to)606-613
Number of pages8
JournalCancer
Volume80
Issue number3 SUPPL.
StatePublished - 1997

Fingerprint

Neoplasms
Hereditary Neoplastic Syndromes
DNA
Genetic Counseling
Insurance
Pedigree
Natural History
Physical Examination
Molecular Biology
Education
Research

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Lemon, S. J., Tinley, S. T., Fusaro, R. M., & Lynch, H. T. (1997). Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience. Cancer, 80(3 SUPPL.), 606-613.

Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience. / Lemon, Stephen J.; Tinley, Susan T.; Fusaro, Ramon M.; Lynch, Henry T.

In: Cancer, Vol. 80, No. 3 SUPPL., 1997, p. 606-613.

Research output: Contribution to journalArticle

Lemon, SJ, Tinley, ST, Fusaro, RM & Lynch, HT 1997, 'Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience', Cancer, vol. 80, no. 3 SUPPL., pp. 606-613.
Lemon, Stephen J. ; Tinley, Susan T. ; Fusaro, Ramon M. ; Lynch, Henry T. / Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience. In: Cancer. 1997 ; Vol. 80, No. 3 SUPPL. pp. 606-613.
@article{7d945f6f731249219d579f0563c1e028,
title = "Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience",
abstract = "BACKGROUND. Hereditary cancer accounts for 5-10{\%} of the estimated 1.38 million cancer cases in 1997 and requires an approach to cancer prevention that is distinct from its sporadic counterpart based on its differing natural history. The laboratory advances in the molecular biology of hereditary cancer have recently resulted in the development of specialized hereditary cancer clinics with both broad and syndrome specific hereditary cancer assessment capabilities. A key question is how well these clinics can accomplish this new mission. METHODS. A total of 58 people underwent hereditary cancer risk assessment in the Creighton University Hereditary Cancer Prevention Clinic from September of 1995 to September of 1996. Assessment included construction of a detailed pedigree and a cancer-directed medical history and physical examination. Cancer education, genetic counseling, the option of DNA testing when appropriate, and cancer prevention recommendations based on cancer risk were provided. RESULTS. The 58 patients were comprised of 51 females (88{\%}) and 7 males (12{\%}) predominantly from the Omaha, Nebraska geographic region. Forty patients (69{\%}) were cancer unaffected whereas 18 (31{\%}) were cancer affected; patient age ranged from 6 to 70 years with a mean age of 40 years. Thirty (52{\%}) of the patient families were diagnosed with a hereditary cancer syndrome, 24 (41{\%}) were diagnosed with familial cancer risk, and 4 (7{\%}) were diagnosed with sporadic cancer risk. Of the 30 families with hereditary cancer syndromes, only 4 (13{\%}) individuals have so far undergone DNA testing due to a variety of emotional, financial, insurance, and technical barriers. CONCLUSIONS. The authors have successfully implemented a clinically applicable hereditary cancer prevention program based on their expertise in hereditary cancer risk assessment that offers DNA testing through a commercial laboratory to patients diagnosed with hereditary cancer syndromes. However, a number of barriers to DNA evaluations exist that will require discussion among the medical, legislative, insurance, and lay communities in addition to further research in hereditary cancer risk assessment, genetic counseling, and cancer prevention strategies.",
author = "Lemon, {Stephen J.} and Tinley, {Susan T.} and Fusaro, {Ramon M.} and Lynch, {Henry T.}",
year = "1997",
language = "English",
volume = "80",
pages = "606--613",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Cancer risk assessment in a Hereditary Cancer Prevention Clinic and its first year's experience

AU - Lemon, Stephen J.

AU - Tinley, Susan T.

AU - Fusaro, Ramon M.

AU - Lynch, Henry T.

PY - 1997

Y1 - 1997

N2 - BACKGROUND. Hereditary cancer accounts for 5-10% of the estimated 1.38 million cancer cases in 1997 and requires an approach to cancer prevention that is distinct from its sporadic counterpart based on its differing natural history. The laboratory advances in the molecular biology of hereditary cancer have recently resulted in the development of specialized hereditary cancer clinics with both broad and syndrome specific hereditary cancer assessment capabilities. A key question is how well these clinics can accomplish this new mission. METHODS. A total of 58 people underwent hereditary cancer risk assessment in the Creighton University Hereditary Cancer Prevention Clinic from September of 1995 to September of 1996. Assessment included construction of a detailed pedigree and a cancer-directed medical history and physical examination. Cancer education, genetic counseling, the option of DNA testing when appropriate, and cancer prevention recommendations based on cancer risk were provided. RESULTS. The 58 patients were comprised of 51 females (88%) and 7 males (12%) predominantly from the Omaha, Nebraska geographic region. Forty patients (69%) were cancer unaffected whereas 18 (31%) were cancer affected; patient age ranged from 6 to 70 years with a mean age of 40 years. Thirty (52%) of the patient families were diagnosed with a hereditary cancer syndrome, 24 (41%) were diagnosed with familial cancer risk, and 4 (7%) were diagnosed with sporadic cancer risk. Of the 30 families with hereditary cancer syndromes, only 4 (13%) individuals have so far undergone DNA testing due to a variety of emotional, financial, insurance, and technical barriers. CONCLUSIONS. The authors have successfully implemented a clinically applicable hereditary cancer prevention program based on their expertise in hereditary cancer risk assessment that offers DNA testing through a commercial laboratory to patients diagnosed with hereditary cancer syndromes. However, a number of barriers to DNA evaluations exist that will require discussion among the medical, legislative, insurance, and lay communities in addition to further research in hereditary cancer risk assessment, genetic counseling, and cancer prevention strategies.

AB - BACKGROUND. Hereditary cancer accounts for 5-10% of the estimated 1.38 million cancer cases in 1997 and requires an approach to cancer prevention that is distinct from its sporadic counterpart based on its differing natural history. The laboratory advances in the molecular biology of hereditary cancer have recently resulted in the development of specialized hereditary cancer clinics with both broad and syndrome specific hereditary cancer assessment capabilities. A key question is how well these clinics can accomplish this new mission. METHODS. A total of 58 people underwent hereditary cancer risk assessment in the Creighton University Hereditary Cancer Prevention Clinic from September of 1995 to September of 1996. Assessment included construction of a detailed pedigree and a cancer-directed medical history and physical examination. Cancer education, genetic counseling, the option of DNA testing when appropriate, and cancer prevention recommendations based on cancer risk were provided. RESULTS. The 58 patients were comprised of 51 females (88%) and 7 males (12%) predominantly from the Omaha, Nebraska geographic region. Forty patients (69%) were cancer unaffected whereas 18 (31%) were cancer affected; patient age ranged from 6 to 70 years with a mean age of 40 years. Thirty (52%) of the patient families were diagnosed with a hereditary cancer syndrome, 24 (41%) were diagnosed with familial cancer risk, and 4 (7%) were diagnosed with sporadic cancer risk. Of the 30 families with hereditary cancer syndromes, only 4 (13%) individuals have so far undergone DNA testing due to a variety of emotional, financial, insurance, and technical barriers. CONCLUSIONS. The authors have successfully implemented a clinically applicable hereditary cancer prevention program based on their expertise in hereditary cancer risk assessment that offers DNA testing through a commercial laboratory to patients diagnosed with hereditary cancer syndromes. However, a number of barriers to DNA evaluations exist that will require discussion among the medical, legislative, insurance, and lay communities in addition to further research in hereditary cancer risk assessment, genetic counseling, and cancer prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=0030742054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030742054&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030742054

VL - 80

SP - 606

EP - 613

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3 SUPPL.

ER -